279 related articles for article (PubMed ID: 23821455)
1. Clinical outcome of hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): experience from a single institution.
Doki N; Ohashi K; Oshikawa G; Kobayashi T; Kakihana K; Sakamaki H
Pathol Oncol Res; 2014 Jan; 20(1):61-6. PubMed ID: 23821455
[TBL] [Abstract][Full Text] [Related]
2. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
[TBL] [Abstract][Full Text] [Related]
3. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
[TBL] [Abstract][Full Text] [Related]
5. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XY; Han W; Zhang XH; Wang Y; Zhang YY; Qin YZ; Liu YR; Huang XJ
J Hematol Oncol; 2012 Jun; 5():29. PubMed ID: 22682059
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic significance of Ph-positive acute lymphoblastic leukemia].
Zhou L; Hu J; Chen J; Du S; Wang A; You J; Wu W; Shen Z; Li J
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):109-13. PubMed ID: 24606650
[TBL] [Abstract][Full Text] [Related]
7. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Hatta Y; Mizuta S; Matsuo K; Ohtake S; Iwanaga M; Sugiura I; Doki N; Kanamori H; Ueda Y; Yoshida C; Dobashi N; Maeda T; Yujiri T; Monma F; Ito Y; Hayakawa F; Takeuchi J; Kiyoi H; Miyazaki Y; Naoe T
Ann Hematol; 2018 Sep; 97(9):1535-1545. PubMed ID: 29694642
[TBL] [Abstract][Full Text] [Related]
8. The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zhang FH; Ling YW; Zhai X; Zhang Y; Huang F; Fan ZP; Zhou HS; Jiang QL; Sun J; Liu QF
Hematology; 2013 May; 18(3):151-7. PubMed ID: 23394269
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xie M; Shi T; Jiang Q; Jia Y; Zhou D; Tong H; Jin J; Zhu HH
Cancer; 2023 May; 129(10):1523-1536. PubMed ID: 36882308
[TBL] [Abstract][Full Text] [Related]
10. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.
Fielding AK; Rowe JM; Richards SM; Buck G; Moorman AV; Durrant IJ; Marks DI; McMillan AK; Litzow MR; Lazarus HM; Foroni L; Dewald G; Franklin IM; Luger SM; Paietta E; Wiernik PH; Tallman MS; Goldstone AH
Blood; 2009 May; 113(19):4489-96. PubMed ID: 19244158
[TBL] [Abstract][Full Text] [Related]
11. Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ohno R
Curr Hematol Malig Rep; 2010 Oct; 5(4):213-21. PubMed ID: 20652453
[TBL] [Abstract][Full Text] [Related]
12. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
[TBL] [Abstract][Full Text] [Related]
13. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
[TBL] [Abstract][Full Text] [Related]
14. Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study.
Hulegårdh E; Hägglund H; Ahlberg L; Karlsson K; Karbach H; Markuszewska A; Persson I; Åström M; Hallböök H
Med Oncol; 2014 Aug; 31(8):66. PubMed ID: 24965535
[TBL] [Abstract][Full Text] [Related]
15. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia.
Mizuta S; Matsuo K; Yagasaki F; Yujiri T; Hatta Y; Kimura Y; Ueda Y; Kanamori H; Usui N; Akiyama H; Miyazaki Y; Ohtake S; Atsuta Y; Sakamaki H; Kawa K; Morishima Y; Ohnishi K; Naoe T; Ohno R
Leukemia; 2011 Jan; 25(1):41-7. PubMed ID: 20944676
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lou Y; Ma Y; Li C; Suo S; Tong H; Qian W; Mai W; Meng H; Yu W; Mao L; Wei J; Xu W; Jin J
Front Med; 2017 Jun; 11(2):229-238. PubMed ID: 28349299
[TBL] [Abstract][Full Text] [Related]
17. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
[TBL] [Abstract][Full Text] [Related]
19. Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.
Zeng Q; Xiang B; Liu Z
Cancer Med; 2021 Dec; 10(24):8741-8753. PubMed ID: 34761879
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]